Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adolescent pregnancy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    275 result(s) found for: Adolescent pregnancy. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005830-63 Sponsor Protocol Number: 0485-CL-0004 Start Date*: 2009-10-30
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003253-36 Sponsor Protocol Number: LBS-008-CT03 Start Date*: Information not available in EudraCT
    Sponsor Name:Belite Bio, Inc
    Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
    Medical condition: Stargardt Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000839-33 Sponsor Protocol Number: LP0053-1108 Start Date*: 2016-03-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety and Effect of LEO 90100 aerosol foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) with Plaque Psoriasis A phase 2 trial evaluating the safety and e...
    Medical condition: Plague Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-003124-41 Sponsor Protocol Number: 219510 Start Date*: 2023-03-27
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3b, non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV ...
    Medical condition: Pregnancy related outcomes and events in maternal participants who were vaccinated against RSV or received control, and in their infants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10070538 Gestational hypertension PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    25.0 10036585 - Pregnancy, puerperium and perinatal conditions 10086971 Pre-eclampsia with severe features LLT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10070532 Fetal growth restriction LLT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10073024 Preterm premature rupture of membranes PT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10075863 Preterm labor LLT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10018210 Gestational diabetes mellitus LLT
    20.0 100000004862 10008755 Chorioamnionitis LLT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10041093 Small for gestational age LLT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10067508 Low birth weight baby PT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10067509 Very low birth weight baby LLT
    21.1 10036585 - Pregnancy, puerperium and perinatal conditions 10074164 Extremely low birth weight baby LLT
    20.1 10018065 - General disorders and administration site conditions 10011912 Death neonatal PT
    25.0 10042613 - Surgical and medical procedures 10086969 Medically induced preterm birth PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) BE (Completed) DE (Completed) FR (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002780-42 Sponsor Protocol Number: TR701-111 Start Date*: 2015-06-29
    Sponsor Name:Trius Therapeutics [...]
    1. Trius Therapeutics
    2. Cubist Pharmaceuticals, Inc
    Full Title: A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Ad...
    Medical condition: Acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10040879 Skin investigations HLGT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000685-12 Sponsor Protocol Number: MC2-01-C6 Start Date*: Information not available in EudraCT
    Sponsor Name:MC2 Therapeutics Ltd
    Full Title: A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Ado...
    Medical condition: Extensive Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-001615-78 Sponsor Protocol Number: F1J-MC-HMGW Start Date*: 2018-05-02
    Sponsor Name:
    Full Title: Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome
    Medical condition: Juvenile Primary Fibromyalgia Syndrome
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005058-27 Sponsor Protocol Number: 165-306 Start Date*: Information not available in EudraCT
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized...
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10034873 Phenylketonuria (PKU) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014368-20 Sponsor Protocol Number: CNTO1275PSO3006 Start Date*: 2011-01-06
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-t...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) PT (Completed) FR (Completed) BE (Completed) HU (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005456-24 Sponsor Protocol Number: MBL 0412 INT Start Date*: 2010-04-02
    Sponsor Name:LEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S)
    Full Title: Safety and Efficacy of Calcipotriol plus Betamethasone Dipropionate Gel in Adolescent Patients (Aged 12 to 17 Years) with Scalp Psoriasis
    Medical condition: Psoriasis of the scalp.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001963-37 Sponsor Protocol Number: GED-0301-CD-004 Start Date*: 2016-02-18
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn’s disease
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10021315 Ileitis terminal LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) SK (Completed) SE (Completed) HU (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) BG (Prematurely Ended) GR (Completed) HR (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001259-37 Sponsor Protocol Number: D3741C00012 Start Date*: 2020-06-26
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003516-39 Sponsor Protocol Number: BUL-3/EER Start Date*: 2021-04-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment...
    Medical condition: Maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003688-25 Sponsor Protocol Number: INS1007-301 Start Date*: 2021-04-08
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10038738 - Respiratory, thoracic and mediastinal disorders 10083611 Non-cystic fibrosis bronchiectasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018911-13 Sponsor Protocol Number: 31-09-267 Start Date*: 2011-06-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia...
    Medical condition: Schizophrenia in Adolescent Patients or Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002067-14 Sponsor Protocol Number: 3151A6-2001 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Research
    Full Title: 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent O...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004335-24 Sponsor Protocol Number: CC-93538-EE-002 Start Date*: 2022-01-14
    Sponsor Name:Celgene International II Sàrl
    Full Title: A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000127-12 Sponsor Protocol Number: TM006 Start Date*: 2022-01-03
    Sponsor Name:Saniona A/S
    Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects ...
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005501-28 Sponsor Protocol Number: A1281134 Start Date*: 2006-05-04
    Sponsor Name:Pfizer AB
    Full Title: Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039626 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001086-27 Sponsor Protocol Number: D3250C00021 Start Date*: 2014-11-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inh...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) PL (Completed) DE (Completed) SE (Completed) BG (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 23:10:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA